Jennifer Bierach
Pulmonary Disease · Tulsa, OKNPI 1043352198
Payments from drug & device makers
What this record shows
This record is dominated by education: $114,015 of the $140,871 with a category attached, or 80.9%. Intuitive Surgical accounts for 98.3% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2023 at $65,086 and has fallen 96.9% since, to $2,035 in 2025. Among pulmonary disease clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 259 payments — averaging $543.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$139K
- Mylan Specialty L.p.$533
- Genentech USA, Inc.$290
- AstraZeneca$246
- Actelion Pharmaceuticals US, Inc.$238
- GSK$164
- plus $891 from 23 others
What the payments were for
- Speaking & faculty fees$10,5007%
- Travel & lodging$6,7935%
- Food & beverage$9,3997%
- Education$114,01581%
- Gifts$1650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 117 | $138,510 |
| Mylan Specialty L.p. | 30 | $533 |
| Genentech USA, Inc. | 19 | $290 |
| AstraZeneca | 12 | $246 |
| Actelion Pharmaceuticals US, Inc. | 9 | $238 |
| GSK | 17 | $164 |
| Boehringer Ingelheim | 12 | $162 |
| AbbVie(2 entities) | 6 | $116 |
| Baxter Healthcare | 3 | $79 |
| Amgen | 3 | $71 |
| Optinose US, Inc. | 4 | $57 |
| Grifols USA, LLC | 2 | $44 |
| Sunovion Pharmaceuticals Inc. | 4 | $41 |
| Insmed, Inc. | 2 | $39 |
| Boston Scientific | 2 | $35 |
| Electromed, Inc. | 3 | $35 |
| Circassia Inc. | 2 | $25 |
| Novartis | 1 | $23 |
| United Therapeutics Corporation | 1 | $20 |
| Sanofi | 1 | $20 |
| Chiesi USA, Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Portola Pharmaceuticals, LLC | 1 | $16 |
| Merck | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $12 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
| Zyla Life Sciences, Inc. | 1 | $11 |
| Veran Medical Technologies, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$131,618
- DA VINCI SP$6,000
How this compares
$140,871 in reported general payments places this provider in the 95th percentile of 133 pulmonary disease providers in Oklahoma.
Other pulmonary disease in Tulsa
- Hassan AbouhouliTulsa$103K
- Grace KennedyTulsa$57K
- Walter BoomerTulsa$43K
- Emil SchelbarTulsa$20K
- Andrew GottehrerTulsa$16K
- Bradley EdgingtonTulsa$12K
- Habiba HussainTulsa$10K
- Conner MoslanderTulsa$9K
- Pratyaksha SankhyanTulsa$9K
- Priyanka PathaniaTulsa$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.